AML, Adult
Conditions
Brief summary
Acute myeloid leukemia (AML) is a highly fatal malignancy in China, with particularly poor outcomes in elderly patients. Low-intensity regimens yield low remission rates, and median overall survival (OS) typically remains under 6-9 months. Venetoclax (VEN) combined with hypomethylating agents (azacitidine or decitabine（DEC）) has emerged as a first-line therapy for these patients, significantly improving response rates and survival. However, challenges persist, including suboptimal complete remission (CR) rates, low Measurable Residual Disease（MRD） negativity, and tolerability issues with prolonged use. Recent studies suggest that a 3-day decitabine regimen combined with VEN may enhance efficacy and tolerability. Building on prior evidence and our institutional experience, we propose this study to evaluate an optimized dosing strategy of VEN plus decitabine in treatment-naïve elderly or chemotherapy-ineligible AML patients, aiming to further improve clinical outcomes.
Interventions
DRUGVEN + DEC
Induction regimen Venetoclax (VEN): Day1-10 Decitabine (DEC):20mg/m²/day, Day 2-4 20mg/m² every 8 hours, Day 5-6 FLT3 Inhibitors (for FLT3/ITD+ patients only): Sorafenib or Gilteritinib, Day 8-14 Post-Remission Treatment Venetoclax (VEN): 400 mg/day, Day 1-7 Decitabine (DEC): 20 mg/m² every 8 hours, Day 2-3 (Regimen repeated every 4-6 weeks) FLT3 Inhibitors (for FLT3/ITD+ patients only): Sorafenib or Gilteritinib, Day 8-14
Sponsors
Handan First Hospital
The Second Hospital of Hebei Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients meeting the World Health Organization (WHO) 2022 diagnostic criteria for acute myeloid leukemia (AML), excluding:Acute promyelocytic leukemia (APL) AML with recurrent genetic abnormalities, including:t(8;21)(RUNX1::RUNX1T1) inv(16)(p13.1q22) or t(16;16)(p13.1q22)/CBFβ::MYH11 2. Patients classified as AML, not otherwise specified (NOS) per WHO criteria, excluding:Acute panmyelosis with myelofibrosis 、Myeloid sarcoma 3. Age and fitness criteria: -Group A: Age ≥65 years (unwilling to receive intensive chemotherapy) Group B: Age \>18 years and ineligible for standard-dose chemotherapy, defined by ≥1 of the following:ECOG performance status 2 or 3；History of chronic heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) ≤50% DLCO ≤65% or FEV1 ≤65%Creatinine clearance ≥30 mL/min but ≤45 mL/min (Cockcroft-Gault or 24-hour urine collection)、Any other condition deemed incompatible with standard chemotherapy (requires PI approval) 4. No prior AML therapy, except:Hydroxyurea、Low-dose cytarabine (\<1.0 g/day) 5. ECOG performance status ≤3 6. Laboratory requirements (within 7 days prior to treatment):AST/ALT/ALP ≤3×ULN (≤5×ULN if due to leukemic involvement)、Total bilirubin ≤2×ULN、Cardiac enzymes \<2×ULN、Serum creatinine clearance ≥30 mL/min (measured or calculated) 7. Contraception requirements:Negative pregnancy test (within 72 hours before treatment) for women of childbearing potential；Agreement to use effective contraception during treatment and for 3 years after therapy 8. Life expectancy ≥2 months 9. Informed consent:Signed by patient, legal guardian, or immediate family member (if patient is unable to consent due to medical condition)
Exclusion criteria
1. AML with BCR::ABL1 fusion or chronic myeloid leukemia (CML) in blast crisis. 2. Previously treated AML patients (received prior induction chemotherapy, regardless of response). 3. Secondary AML, including:Therapy-related AML (per WHO classification)、AML with prior history of myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) 4. Concurrent hematologic disorders (e.g., hemophilia, myelofibrosis, or other conditions deemed ineligible by the investigator). Exception: Patients with prior blood count abnormalities but confirmed non-MDS/MPN by bone marrow examination may be included. 5. Pregnant or lactating women. 6. Hypersensitivity to any study drugs. 7. Use of strong/moderate CYP3A4 inducers within 3 days prior to treatment initiation. 8. Active malignancy in other organs (requiring treatment). 9. Clinically significant hepatic/renal dysfunction exceeding inclusion criteria limits. 10. Active cardiac disease, defined as ≥1 of the following:Myocardial infarction within 6 months before enrollment；History of symptomatic arrhythmia requiring medication；Uncontrolled/symptomatic congestive heart failure (NYHA Class \>2) 11. Active infections, including:Untreated tuberculosis or pulmonary aspergillosis Known HIV, active hepatitis B (HBV), or hepatitis C (HCV) 12. Central nervous system (CNS) leukemia at baseline. 13. Medical history of:Epilepsy requiring medication、Dementia or psychiatric disorders impairing protocol compliance 14. Conditions limiting oral drug absorption (e.g., malabsorption syndrome). 15. Investigator's discretion for ineligibility.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the Complete Remission (CR) Rate after Cycle 1 | up to 42 days after treatment |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | Within 5 years after randomization |
| Relapse-Free Survival Rate (RFS) | Within 5 years after randomization |
| Cumulative incidence of relapse | Within 5 years after randomization |
Countries
China
Contacts
Primary ContactLING XI GUO
Outcome results
None listed